No Data
No Data
Minsheng Securities released a research report on April 27 stating that it gave Doctor Glasses (300622.SZ) a recommended rating. The main reasons for the rating include: 1) incident: Dr. Glasses released its 2024 quarterly report; 2) the year-on-year decl
Minsheng Securities released a research report on April 27 stating that it gave Doctor Glasses (300622.SZ) a recommended rating. The main reasons for the rating include: 1) incident: Dr. Glasses released its 2024 quarterly report; 2) the year-on-year decline in the local lifestyle service business affected the company's revenue growth rate, expecting steady sales growth due to further business adjustments; 3) Continued refinement of the franchise model to enable the expansion of the sinking market. By the end of 24Q1, the Concrete Glasses Alliance platform had a total of 598 franchise store users who completed the franchise signing process; 4) The gross margin was relatively stable, and a slight increase in sales expenses affected profitability. (The Daily Sutra
Doctor Glasses (300622) Quarterly Report Review: Under a high base, performance is slightly pressured, and digital retail is progressing steadily
The company released its 2024 quarterly report: the company achieved revenue of 296 million yuan (-4.5% year over year), net profit of 25 million yuan (YoY -32.9%), net profit of 23 million yuan (year-on-year) after deducting net profit of not attributable to mother of 0.23 million yuan (year-on-year -35)
Dr. Glasses (300622): Due to weak consumption, passenger flow is under pressure, revenue is stable, but net profit has declined a lot
Dr. Glasses revealed its quarterly report: In Q1, the company achieved revenue of 296 million yuan/-4.47% year over year, with a return of 25 million yuan/-32.85% year over year, after deducting not 23 million yuan/year on year -35.07%.
Dr. Glasses (300622.SZ): Net profit of 2,535,500 yuan in the first quarter decreased by 32.85% year on year
On April 25, Ge Longhui (300622.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 296 million yuan, down 4.47% year on year; net profit attributable to shareholders of listed companies was 25.355 million yuan, down 32.85% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 22.9386 million yuan, down 35.07% year on year; basic earnings per share were 0.14 yuan.
Express News | Dr. Glasses: The company's retail eyewear scale accounts for about 1% of China's eyewear product market
Dr. Glasses (300622): Net profit to mother +69% Online, local lifestyle, shopping malls and medical stores are the three major growth points
Revenue from key investment points grew steadily. Net profit to mother increased by 69% in line with expectations, while profitability rose steadily, revenue increased 22% in 23 years, and net profit to mother increased 69% in line with expectations. Revenue of 1.18 billion yuan in '23, up 22% from the same period, returned to mother
No Data